Sotyktu significantly outperformed placebo for the treatment of psoriatic arthritis in a phase 3 trial, meeting key endpoints ...

Detailed price information for Corcept Therapeutics (CORT-Q) from The Globe and Mail including charting and trades.

Cartesian Therapeutics Inc. unveiled 12-month efficacy and safety data from the phase IIb trial of Descartes-08 in participants with generalized myasthenia gravis (MG). Participants dosed with a ...

Bank of America downgraded high-end furniture retailer RH (NYSE:RH) to Underperform, citing macroeconomic headwinds and sharply higher global tariffs that could erode the company’s earnings power and ...

Alumis and Acelyrin have filed a definitive proxy statement/prospectus with the US Securities and Exchange Commission for the ...